Letrozol Accord

Letrozole, the active ingredient in Letrozol Accord, is an aromatase inhibitor presented as an oral tablet for oral use. Approved in the European Union, it is used in endocrine therapy to reduce estrogen production in hormone receptor‑positive breast cancer among postmenopausal women.

GNH USA supplies Letrozol Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, with full regulatory compliance and quality assurance. The product meets EU pharmacopeial standards and is manufactured under GMP conditions.

Letrozole is an aromatase inhibitor used in the treatment of hormone‑dependent breast cancer. - Hormone receptor‑positive breast cancer (postmenopausal): Reduces estrogen synthesis to inhibit tumor growth. - Adjuvant therapy for early‑stage breast cancer: Decreases risk of recurrence after surgery. - Metastatic breast cancer (postmenopausal): Provides disease control when other endocrine agents are insufficient.

Letrozole may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Hot flashes: Sudden feeling of warmth and sweating. - Arthralgia: Joint pain or stiffness. - Fatigue: Persistent tiredness. - Nausea: Upset stomach or urge to vomit. - Headache: Mild to moderate cranial pain. - Insomnia: Difficulty falling or staying asleep.

Serious or Rare Side Effects: - Severe liver injury: Jaundice, elevated enzymes. - Osteoporotic fractures: Increased bone fragility. - Pulmonary embolism: Sudden shortness of breath. - Deep vein thrombosis: Leg swelling and pain. - Anaphylaxis: Rapid onset of allergic reaction. - Hypercholesterolemia: Elevated blood cholesterol levels.

When prescribing Letrozol Accord, clinicians should consider several safety measures. - Monitor bone density: Assess risk of osteoporosis and fractures. - Evaluate liver function: Perform baseline and periodic hepatic tests. - Assess cardiovascular risk: Watch for thromboembolic events. - Contraindicated in pregnancy: Category X, avoid use in pregnant women. - Caution with estrogen therapy: May reduce efficacy of Letrozole. - Store at ambient temperature: Keep in original container, protect from moisture and direct sunlight.

Letrozole can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Concomitant estrogen replacement therapy: Opposes aromatase inhibition. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): Decrease Letrozole plasma levels. - Other aromatase inhibitors: Redundant pharmacologic effect.

Moderate Interactions (Monitor Closely): - CYP2C19 inhibitors (e.g., fluoxetine): May increase Letrozole exposure. - Warfarin: Potential alteration of anticoagulant effect. - Glucocorticoids: May affect estrogen metabolism.